CO6650398A2 - Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a - Google Patents

Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a

Info

Publication number
CO6650398A2
CO6650398A2 CO13052484A CO13052484A CO6650398A2 CO 6650398 A2 CO6650398 A2 CO 6650398A2 CO 13052484 A CO13052484 A CO 13052484A CO 13052484 A CO13052484 A CO 13052484A CO 6650398 A2 CO6650398 A2 CO 6650398A2
Authority
CO
Colombia
Prior art keywords
compounds
disorders associated
treatment
ht1a
receptors
Prior art date
Application number
CO13052484A
Other languages
English (en)
Inventor
Torres Russo Valter Freire
De Souza Russo Elisa Mannochio
Original Assignee
Ache Lab Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Lab Farmaceuticos Sa filed Critical Ache Lab Farmaceuticos Sa
Publication of CO6650398A2 publication Critical patent/CO6650398A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está relacionada con los compuestos de alquil-piperazino-fenil 4(3H)-quinazolinona de fórmula general (I), farmacológicamente activos y capaces de actuar sobre los receptores serotoninérgicos 5-HT1A y 5-HT2A de forma de promover el control, alivio o la cura de trastornos asociados a estos receptores y, a las composiciones farmacéuticas que contienen los compuestos para el tratamiento de trastornos asociados a estos receptores. Estos compuestos y sus composiciones farmacéuticas son útiles en el tratamiento de trastornos de depresión, ansiedad, fobias, adicciones, agresividad, impulsividad, pánico, alimentarios, del sueño, psicóticos, trastorno obsesivo-compulsivo, disfunciones sexuales femeninas, entre otros trastornos asociados a estos receptores.
CO13052484A 2010-09-24 2013-03-15 Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a CO6650398A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI1003506-0 BRPI1003506B1 (pt) 2010-09-24 2010-09-24 composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Publications (1)

Publication Number Publication Date
CO6650398A2 true CO6650398A2 (es) 2013-04-15

Family

ID=44903021

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13052484A CO6650398A2 (es) 2010-09-24 2013-03-15 Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a

Country Status (12)

Country Link
US (6) US8735578B2 (es)
EP (1) EP2619187B1 (es)
AR (2) AR083166A1 (es)
BR (1) BRPI1003506B1 (es)
CL (1) CL2012003539A1 (es)
CO (1) CO6650398A2 (es)
DK (1) DK2619187T3 (es)
ES (1) ES2538105T3 (es)
MX (1) MX2013002955A (es)
PE (1) PE20130512A1 (es)
PT (1) PT2619187E (es)
WO (1) WO2012037634A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016186909A1 (en) 2015-05-18 2016-11-24 Mayo Foundation For Medical Education And Research Percutaneously-deployable prosthetic tricuspid valve
DK3130339T3 (da) * 2015-08-14 2020-08-03 Aché Laboratorios Farmaceuticos Sa Forbindelse til anvendelse i behandlingen af komorbid angstlidelse og depressionslidelse
CN111601600A (zh) * 2017-12-14 2020-08-28 艾奇实验室制药有限公司 创伤后综合征障碍的治疗
WO2022232693A1 (en) * 2021-04-30 2022-11-03 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
WO2024042480A1 (en) 2022-08-26 2024-02-29 Suven Life Sciences Limited Heteroaromatic compounds for the treatment of neurological disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB420398A (en) 1933-08-28 1934-11-30 Stanley John Corbin Improvements in clips for making electrical connections
US3047462A (en) 1959-03-06 1962-07-31 Lab Jacques Logeais Soc D Expl Quinazolone anti-inflammatory composition
US3086910A (en) 1960-03-09 1963-04-23 Wallace & Tiernan Inc Central nervous system depressants 3-(2'-pyridyl)-4-quinazolones
US3073826A (en) 1960-10-20 1963-01-15 Mead Johnson & Co 3-pyrrolidylmethyl-4-quinazolones
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
US3231572A (en) 1963-08-05 1966-01-25 Miles Lab 3-substituted-4-quinazolones
US3448109A (en) 1966-08-01 1969-06-03 Boehringer Sohn Ingelheim Certain amino-substituted 2-methyl-3-phenyl-4(3h)-quinazolinones
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3726979A (en) 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
GB1466571A (en) 1973-10-23 1977-03-09 Roussel Lab Substituted quinazolone compounds and pharmaceutical uses thereof
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
FI791926A (fi) 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
FR2429212A1 (fr) 1978-06-20 1980-01-18 Synthelabo Derives de phenylpiperazine et leur application en therapeutique
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS58159480A (ja) 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DE3583307D1 (en) 1984-05-10 1991-08-01 Ciba Geigy Ag Benzo-(pyrano und thiopyrano)-pyridine.
US4721787A (en) 1984-05-10 1988-01-26 Ciba-Geigy Corporation Process for the preparation of benzo-(pyrano and thiopyrano)-pyridines
JPS62135464A (ja) 1985-12-10 1987-06-18 Nippon Kayaku Co Ltd フエニルピペラジン誘導体
US4866230A (en) 1987-04-27 1989-09-12 Shin-Etu Handotai Company, Limited Method of and apparatus for controlling floating zone of semiconductor rod
US4797489A (en) 1987-12-02 1989-01-10 American Home Products Corp. Adamantyl- and fluorenyl-arylpiperazines and -arylpiperidines
US5166157A (en) 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
ATE126796T1 (de) 1990-01-02 1995-09-15 Fujisawa Pharmaceutical Co Quinazolinderivate und ihre herstellung.
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
SE9201239D0 (sv) 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors

Also Published As

Publication number Publication date
US20160008360A1 (en) 2016-01-14
CL2012003539A1 (es) 2013-07-26
BRPI1003506A2 (pt) 2013-01-29
WO2012037634A1 (en) 2012-03-29
AR083166A1 (es) 2013-02-06
US20140336199A1 (en) 2014-11-13
US8735578B2 (en) 2014-05-27
US9181201B2 (en) 2015-11-10
US20140303179A1 (en) 2014-10-09
ES2538105T3 (es) 2015-06-17
EP2619187A1 (en) 2013-07-31
DK2619187T3 (en) 2015-06-01
BRPI1003506B1 (pt) 2019-12-03
EP2619187B1 (en) 2015-03-04
US20130184286A1 (en) 2013-07-18
AR118278A2 (es) 2021-09-22
PE20130512A1 (es) 2013-04-27
US9326984B2 (en) 2016-05-03
PT2619187E (pt) 2015-06-30
US20150018365A1 (en) 2015-01-15
US9169218B2 (en) 2015-10-27
US20210338674A1 (en) 2021-11-04
MX2013002955A (es) 2013-10-01

Similar Documents

Publication Publication Date Title
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
DOP2011000218A (es) Derivados de sulfonamida
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
CO6640285A2 (es) 5-alquinil-pirimidinas
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
CO6650398A2 (es) Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CR8928A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
CR10850A (es) Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico
ECSP11010816A (es) Nuevos Compuestos
CL2008002826A1 (es) Compuestos derivados de pirimidina alquiltio sustituidas, antagonista crth2; composicion farmaceutica que comprende a dicho compuestos; y uso para tratar una enfermedad alergica, asma, dermatitis atopica, psoriasis, colitis ulcerantes, sinusitis, leucemia basofilica, entre otras.
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.